http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
용해도 파라미터의 분자동역학 계산을 통한 천연 실크 소재의 혼화성 연구
임근안,최강민,임정우,김영래,박치훈,장해남,Im, Keunan,Choi, Kang-min,Leem, Jung Woo,Kim, Young L.,Park, Chi Hoon,Jang, Hae Nam 한국막학회 2021 멤브레인 Vol.31 No.2
최근 들어 여러 산업 분야에 활발히 사용되고 있는 고분자 분리막은 화학구조의 제어나 제막공정에서의 물리적 특성 제어뿐만 아니라 다양한 소재와 혼합된 복합막 제조를 통해서 고유의 특성을 부여할 수 있는 장점을 가지고 있다. 본 연구에서는 분리막 제조 시에 누에(Bombyx mori)가 생산한 친환경 천연소재로 활용 가능성이 넓은 실크 고분자의 복합막 제조 시 다른 소재와의 혼화성 지표로 사용할 수 있는 용해도 파라미터를 분자동역학을 이용하여 계산하였다. 역시 친환경성 및 생체적합성을 갖고 있는 polyvinylalcohol (PVA)의 용해도 파라미터를 분자동역학을 이용하여 계산 후 서로 비교하였을 때 두 고분자 소재가 비슷한 용해도 파라미터 값을 갖는 것을 확인하였다. 결론적으로, 두 고분자가 서로 잘 혼합될 수 있음을 이론적으로 증명하였고, 실제 실험을 통해서도 이를 확인할 수 있었다. In recent years, polymer membranes, which are actively used in various industrial fields, have the advantage of being able to impart unique properties through the control of chemical structures and physical properties in the film-fabrication process, as well as through fabricating blend membranes mixed with various materials. In this study, the solubility parameter, which can be used as an index of miscibility with other materials, was calculated using molecular dynamics using a silkworm (Bombyx mori) silk polymer which has a wide potential to be used as an eco-friendly natural material. When the solubility parameter of polyvinylalcohol (PVA), which is also environmentally friendly and biocompatible, was calculated by molecular dynamics and compared with each other, it was confirmed that the two polymer materials had similar solubility parameter values. In conclusion, it was theoretically proved that the two polymers could blend well with each other, which was confirmed through experiments.
김혜진(Hyeoi Jin Kim),임정우(Jung Woo Im) 한국체육측정평가학회 2009 한국체육측정평가학회지 Vol.11 No.2
이 연구는 임정우(2009)의 후속연구로써 필드하키 종목의 패스움직임 기록을 이용하여 임정우(2009)에 의해서 보고된 필드하키 종목의 팀 기반 경기내용 분석요인들에 대하여 타당도 증거를 확인하는 것이 목적이다. 팀기반 경기내용분석 요인의 타당도 증거를 확인하기 위해 남자 대학 및 실업팀의 정규 경기를 대상으로 하였다. 구체적으로정규경기 11경기를 비디오로 촬영하였으며, 승리한 팀의 11경기, 패배한 팀의 11경기 전체 22경기로 구분하여 분석에 사용하였다. 연구대상 자료는 정규경기가 녹화된 비디오를 통해 각 팀의 패스 패턴을 MS-Excel 프로그램에 기록하였다. 또한 비주얼베이직(visual basic) 프로그램을 이용해 Excel에 기록된 패스 패턴 자료의 결과를 자동으로 산출하도록 하였다. 통계분석을 위해 SPSS 12.0을 이용하여, 비모수 통계(Nonparametric Statistics) 분석인 kruskal-wallis를 실시하였으며, 상관분석 등의 기술분석과 함께 로지스틱 회귀분석을 통하여 승산비(Odds ratio)를 산출하여 승패에 따른 팀 기반 경기내용분석요인의 승산정도를 분석하였다. 이 때, 모든 분석에서 유의수준은 α=.05에 설정하였다. 이 연구의 결과에 따르면 하키종목 팀기반 경기내용분석 요인 중 셋트플레이 성공도와 공격위협도 등 공격관련 경기내용분석 요인이 높은 값일수록 승리한 경기사례가 많다. 또한 높은 수비조직력 역시 팀 승리와 연관성이 높다. 따라서 하키경기 팀기반의 경기내용분석 요인을 통하여 승패 여부를 평가하는 것은 타당한 것으로 판단된다. 향후 다양한 측면에서 수집된 타당도 증거들은 하키경기분석의 활성화에 도움을 줄 수 있을 것이다. This study was performed to test the validation of analysis factors for match-contents based on hockey team play. For the purpose of this study, we collected the records of 11 regular hockey games by video and analyzed 11 winning games and 11 lost games. Data of patterns of pass during the games were manipulated and analyzed by Visual Basic Program and Excel Program. The data were statistically analyzed by Kruskal-Walliis of Nonparametric statistics, Pearson`s correlations and Odds ratio of Logistic Regression Analysis. According to results, attack-associated factors among match-based play contents have positive relation to winnings of the games. Also, High level of defense was significantly associate with success of the games. Therefore, it is suggested that evaluation of success by team-play-based match-contents analysis is considered validated, and diversity of match-contents for analysis and expectation of success of game will be helpful for hockey game analysis.
주문맥혈전증을 동반한 거대 간세포암 환자에서 정위 체부 방사선치료와 sorafenib 병합으로 종양의 완전관해 유도 후 위궤양천공이 발생한 1예
황상연 ( Sang Youn Hwang ),이선미 ( Seon Mi Lee ),임정우 ( Jung Woo Im ),김준석 ( Joon Suk Kim ),안상부 ( Sang Bu Ahn ),지은경 ( Eun Kyeong Ji ),최철원 ( Chul Won Choi ),양광모 ( Gwang Mo Yang ) 대한간암학회 2014 대한간암학회지 Vol.14 No.1
Hepatocellular carcinoma (HCC) patients with main portal vein invasion have a poor prognosis associated with a median survival time of 2.7 months. Though many guidelines recommended sorafenib in HCC patients with macrovascular invasion (MVI), many clinicians or centers still select locoregional therapy (LRT) such as transarterial chemoembolization (TACE), radiation therapy (RT), or combination with LRT and sorafenib because the survival improvement by sorafenib only is expected to be shorter than that without MVI. However this multidisciplinary approach may increase treatment related toxicity such as liver failure etc. Stereotactic body radiation therapy (SBRT) is new technology providing very highly conformal ablative radiation dose for a small numbers (3-5 fractions) of large fraction size and is expected to new effective modality for HCC with MVI. Based on above suggestions, we herein offer our experience of a patient with perforation of radiation induced gastric ulcer after complete remission of tumor and main portal vein thrombosis by combination therapy of SBRT and sorafenib. Further study, maybe regarding a combination of locoregional and systemic therapy, is necessary on how to manage HCC patients with main portal vein invasion.
주문맥침범과 임파절 전이를 동반한 Child 등급 B인 간세포암 환자에서 방사선치료와 sorafenib 병합으로 종양의 부분관해를 경험한
황상연 ( Sang Youn Hwang ),이선미 ( Seon Mi Lee ),임정우 ( Jung Woo Im ),김준석 ( Joon Suk Kim ),안상부 ( Sang Bu Ahn ),지은경 ( Eun Kyeong Ji ),강현철 ( Hyun Cheol Kang ),최철원 ( Cheol Won Choi ),양광모 ( Gwang Mo Yang ) 대한간암학회 2014 대한간암학회지 Vol.14 No.2
Reserved liver function is one of the most important determinants of survivial in advanced hepatocellular carcinoma (HCC). Especially in cirrhotic patient with decompensated liver function, sorafenib for HCC with main portal vein invasion have limited efficacy and survival benefit. Therefore many clinicians or centers still try locoregional therapy (LRT) such as transarterial chemoembolization (TACE), radiation therapy (RT), or combination with LRT and sorafenib in this situation. However this multidisciplinary approach may increase treatment related toxicity such as liver failure, etc. Recently, studies for combination of RT and sorafenib for HCC with portal vein invasion have been tried and reported not only bettertherapeutic efficacy, but also more hepatic toxicity.Based on above suggestions, we herein offer our experience of a patient that although achieved survival gain via partial remission of intrahepatic tumor and main portal vein thrombosis and metastatic lymph node by combination therapy of RT and sorafenib, finally expired due to hepatictoxicity. Further study, maybe regarding a combination of locoregional and systemic therapy, is necessary on how to manage decompenstated cirrhotic patients with HCC with main portal vein invasion. (J Liver Cancer 2014;14:120-126)
다발성 전이를 동반한 고령의 간세포암 환자에서 경동맥방사선색전술과 반복적 경동맥화학색전술로 간내암과 다발성 전이의 부분관해를 이룬 증례
황상연 ( Sang Youn Hwang ),이선미 ( Seon-mi Lee ),임정우 ( Jung Woo Im ),전기정 ( Ki Jeong Jeon ),안상부 ( Sang Bu Ahn ),박진영 ( Jin-young Park ) 대한간암학회 2018 대한간암학회지 Vol.18 No.2
The number of older adults with hepatocelluar carcinoma (HCC) has been increasing with longer life expectancy and earlier diagnosis and treatment. However, older patients have lesser function reserve of multiple organ systems, more disability rate. Therefore, the treatment of elderly HCC patients remains a challenge worldwide. Recently, studies suggests that the survival outcome of older patients may be comparable to that of younger patients and active treatment may achieve promising rates of local and systemic control in selected patients. Based on above suggestions, we herein offer our experience of a case achieved partial remission by sequential therapy of transarterial chemoembolization after transarterial radioemoblization in elderly HCC patient with multiple metastasis. Further study, maybe regarding a combination of locoregional and systemic treatment, is necessary on how to manage HCC in elderly patients. (J Liver Cancer 2018;18:151-156)
소라페닙 치료 실패 후 소라페닙과 Tegafur 병용요법을 통해 간세포암의 완전관해를 유도한 증례 1예
황상연 ( Sang Youn Hwang ),이선미 ( Seon-mi Lee ),임정우 ( Jung Woo Im ),전기정 ( Ki Jeong Jeon ),안상부 ( Sang Bu Ahn ),박진영 ( Jin-young Park ),최철원 ( Cheol-won Choi ),양광모 ( Kwang-mo Yang ) 대한간암학회 2017 대한간암학회지 Vol.17 No.1
Sorafenib is the only approved targeted agent as the first line systemic therapy for treatment of advanced hepatocellular carcinoma (HCC). However, the improvement of survival duration under 3 months is far from clinical satisfactory and most patients experience disease progression within 6 months after sorafenib therapy. Unfortunately, second line systemic therapy after treatment failure of sorafenib was not established and there were no clear guidelines for salvage treatment modalities. Recently, studies suggests that combination of sorafenib and single cytotoxic agent can be relatively effective and safe strategy that achieves promising rates of local and systemic control in advanced HCC patients. Based on above suggestions, we herein offer our experience of a case achieved complete remission by combination therapy of sorafenib and tegafur in the patient with progressed disease after sorafenib therapy. (J Liver Cancer 2017;17:88-93)
담관 침범을 동반한 저혈관성 간세포암종에서 경동맥화학색전술, 정위 체부 방사선 치료, sorafenib을 병합하여 부분관해를 경험한 1예
황상연 ( Sang Youn Hwang ),이선미 ( Seon Mi Lee ),임정우 ( Jung Woo Im ),김준석 ( Joon Suk Kim ),안상부 ( Sang Bu Ahn ),지은경 ( Eun Kyeong Ji ),최철원 ( Chul Won Choi ),양광모 ( Gwang Mo Yang ) 대한간암학회 2013 대한간암학회지 Vol.13 No.2
Hepatocellular carcinoma (HCC) patients with bile duct invasion have a poor prognosis because many do not receive effective treatment. Surgical resection is thought to be only option of curative treatment, increasing chance of survival, but it is possible to minor group of patients because of poor reserved liver function associated with underlying liver disease and obstructive jaundice. Therefore many clinicians or centers still select locoregional therapy such as transarterial chemoembolization (TACE), radiation therapy (RT) etc. Stereotactic body radiation therapy (SBRT) is new technology providing very highly conformal ablative radiation dose for a small numbers (1-5 fractions) of large fraction size and is expected to salvage modality for HCC showed incomplete response of TACE due to vascularity or accessibility of feeding artery. Based on above suggestions, we herein offer our experience of a patient with partial remission of tumor by combination therapy of TACE, SBRT and sorafenib. Further study, maybe regarding a combination of locoregional and systemic therapy (so called multidisciplinary approach), is necessary on how to manage HCC patients with bile duct invasion or sparse vascularity.
부신, 폐전이를 동반한 거대 간세포암 환자에서 경동맥 화학색전술, 방사선 치료, sorafenib을 병합하여 간내암과 부신전이의 완전관해를 경험한 1예
황상연 ( Sang Youn Hwang ),이선미 ( Seon-mi Lee ),임정우 ( Jung Woo Im ),김준석 ( Joon Suk Kim ),안상부 ( Sang Bu Ahn,),지은경 ( Eun Kyeong Ji ),최철원 ( Chul Won Choi ),양광모 ( Gwang-mo Yang ) 대한간암학회 2013 대한간암학회지 Vol.13 No.1
Extrahepatic metastasis (EHM) associated with hepatocellular carcinoma (HCC) has been increasing due to prolonged survival with recent advances in therapeutic approaches including locoregional therapy such as transarterial chemoemoblization (TACE), radiofrequency ablation and radiation therapy (RT). Though many guidelines recommended systemic therapy such as sorafenib in this situation, some clinicians or centers still select locoregional therapy because the survival improvement of 2 or 3 months by sorafenib is far from optimal. Moreover, some studies showed that complete and partial response of intrahepatic tumors can result in significant improvement of patient survival even in situation of EHM. Based on above suggestions, we herein offer our experience of a patient with complete remission of intrahepatic tumor and adrenal gland metastasis treated with combination therapy of TACE and RT and sorafenib. Further study, maybe regarding a combination of locoregional and systemic therapy (so called multidisciplinary approach), is necessary on how to manage HCC patients with EHM.
동정맥 단락을 동반한 4.8 cm의 침윤성 간세포암에서 정위체부방사선치료와 경동맥화학색전술로 종양의 완전관해를 경험한 1예
황상연 ( Sang Youn Hwang ),이선미 ( Seon Mi Lee ),임정우 ( Jung Woo Im ),김준석 ( Joon Suk Kim ),전기정 ( Ki Jeong Jeon ),안상부 ( Sang Bu Ahn ),지은경 ( Eun Kyeong Ji ),강현철 ( Hyun Cheol Kang ),최철원 ( Cheol Won Choi ),양광모 대한간암학회 2015 대한간암학회지 Vol.15 No.1
Infiltrative hepatocellular carcinoma (HCC) patients have a poor prognosis because most patients present with advanced disease. Although tumor size is small, ablation therapy is difficult because it is difficult to delineate tumor boundary and tumor often combined vascular invasion. Therefore many clinicians still try locoregional therapy (LRT) such as transarterial chemoembolization (TACE), radiation therapy (RT), or combination with LRT and sorafenib in this situation. Stereotactic body radiation therapy (SBRT) is new technology providing very highly conformal ablative radiation dose and is expected to salvage modality for HCC showed incomplete response of TACE due to combined arteriovenous (AV) shunts. Based on above suggestions, we herein offer our experience of a complete remission of tumor by combination of SBRT and TACE in a patient with infiltrative HCC. Further study, maybe regarding a combination of locoregional and systemic therapy is necessary on how to manage infiltrative HCC with AV shunts. (Journal of Liver Cancer 2015;15:64-69)